CA Irvine의 비소세포폐암 임상 시험
비소세포폐암 관련 연구 25개가 Irvine 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
연구 대상자를 모집 중이신가요? 이 페이지 상단에 노출하세요 — 30일 동안 $99 →
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
피험자 모집 중3상
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 263144, Irvine
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
피험자 모집 중2/3상
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 277928, Irvine
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
피험자 모집 중3상
- Kaiser Permanente-Irvine, Irvine
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
피험자 모집 중1상
- City of Hope at Irvine Lennar, Irvine
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
피험자 모집 중2상
- City of Hope 1, Irvine
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
피험자 모집 중2상
- City of Hope Orange County Lennar Foundation Cancer Center, Irvine
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
피험자 모집 중2상
- The City of Hope Orange County Lennar Foundation Cancer Center, Irvine
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
피험자 모집 중2/3상
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care building, Irvine
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
피험자 모집 중1상
- Hoag Memorial Hospital Presbyterian, Irvine
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
피험자 모집 중3상
- UCI Health-CIACC, Irvine
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
피험자 모집 중3상
- Research Site, Irvine
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
피험자 모집 중1/2상
- City of Hope, Irvine
Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
피험자 모집 중2상
- City of Hope at Irvine Lennar, Irvine
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
피험자 모집 중1/2상
- The Regents of the University of California - Irvine, CA Campus, Irvine
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
피험자 모집 중1상
- Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
피험자 모집 중3상
- City of Hope at Irvine Lennar, Irvine
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
피험자 모집 중1/2상
- City of Hope - Lennar, Irvine
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
피험자 모집 중1상
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 278589, Irvine
Study of XB010 in Subjects With Solid Tumors
피험자 모집 중1상
- City of Hope Orange County Lennar Foundation Cancer Center, Irvine
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
피험자 모집 중2/3상
- City of Hope at Irvine Lennar, Irvine
- Kaiser Permanente-Irvine, Irvine
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
피험자 모집 중2상
- City of Hope at Irvine Lennar, Irvine
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
피험자 모집 중1/2상
- University of California, Irvine, Irvine
Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer
피험자 모집 중1상
- City of Hope at Irvine Lennar, Irvine
Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer
피험자 모집 중2상
- City of Hope at Irvine Lennar, Irvine
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
피험자 모집 중관찰 연구
- Massive Bio SYNERGY-AI site, Irvine
다른 도시의 비소세포폐암 시험
- Houston, TX연구 145개
- New York City, NY연구 121개
- Arlington, VA연구 104개
- Nashville, TN연구 97개
- Boston, MA연구 90개
- Los Angeles, CA연구 87개
- St. Louis, MO연구 73개
- Chicago, IL연구 61개
- Baltimore, MD연구 60개
- San Antonio, TX연구 59개
- Columbus, OH연구 57개
- Washington, DC연구 55개
Irvine의 다른 연구
- 유방암연구 23개
- 암 (전체)연구 17개
- 전이성 암연구 16개
- 폐암연구 15개
- 다발성 골수종연구 14개
- 전립선암연구 14개
- 난소암연구 12개
- 두경부 편평세포암연구 11개
- 방광암연구 11개
- 알츠하이머병연구 11개
- 대장직장암연구 10개
- 췌장암연구 10개
ClinicalTrials.gov 출처, 2026. 10. 6. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.